NASDAQ:ICU - Nasdaq - US81256L2034 - Common Stock - Currency: USD
1.81
+0.06 (+3.43%)
The current stock price of ICU is 1.81 USD. In the past month the price decreased by -8.12%. In the past year, price decreased by -91.12%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 29.37 | 237.84B | ||
ISRG | INTUITIVE SURGICAL INC | 70.7 | 184.84B | ||
BSX | BOSTON SCIENTIFIC CORP | 39.49 | 146.29B | ||
SYK | STRYKER CORP | 31.12 | 144.73B | ||
MDT | MEDTRONIC PLC | 17.7 | 121.20B | ||
BDX | BECTON DICKINSON AND CO | 16.5 | 65.91B | ||
EW | EDWARDS LIFESCIENCES CORP | 26.84 | 41.35B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 19.28 | 39.59B | ||
IDXX | IDEXX LABORATORIES INC | 38.23 | 34.98B | ||
RMD | RESMED INC | 26.29 | 34.14B | ||
DXCM | DEXCOM INC | 47.18 | 30.42B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 18.25 | 25.91B |
SeaStar Medical Holding Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Denver, Colorado and currently employs 12 full-time employees. The company went IPO on 2021-01-26. SeaStar Medical Holding Corporation is a commercial-stage medical technology company. The firm is focused on developing extracorporeal therapies to reduce the consequences of hyperinflammation on vital organs. The firm's technologies rely on science to provide life-saving solutions to critically ill patients. The firm develops and commercializes cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The firm uses its Selective Cytopheretic Device (SCD) technology platform to clinically validate several acute organ injury indications, including kidneys and lungs. Its investigational SCD is an extracorporeal synthetic membrane device designed to integrate into existing continuous renal replacement therapy (CRRT) systems that are commonly installed in hospitals throughout the United States.
SEASTAR MEDICAL HOLDING CORP
3513 Brighton Blvd, Suite 410
Denver COLORADO US
Employees: 12
Company Website: https://seastarmedical.com
Investor Relations: https://investors.seastarmedical.com/overview/default.aspx
Phone: 18444278100
The current stock price of ICU is 1.81 USD. The price increased by 3.43% in the last trading session.
The exchange symbol of SEASTAR MEDICAL HOLDING CORP is ICU and it is listed on the Nasdaq exchange.
ICU stock is listed on the Nasdaq exchange.
5 analysts have analysed ICU and the average price target is 7.14 USD. This implies a price increase of 294.48% is expected in the next year compared to the current price of 1.81. Check the SEASTAR MEDICAL HOLDING CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SEASTAR MEDICAL HOLDING CORP (ICU) has a market capitalization of 15.78M USD. This makes ICU a Nano Cap stock.
SEASTAR MEDICAL HOLDING CORP (ICU) currently has 12 employees.
SEASTAR MEDICAL HOLDING CORP (ICU) has a support level at 1.57 and a resistance level at 1.82. Check the full technical report for a detailed analysis of ICU support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ICU does not pay a dividend.
SEASTAR MEDICAL HOLDING CORP (ICU) will report earnings on 2025-04-14, after the market close.
SEASTAR MEDICAL HOLDING CORP (ICU) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.38).
The outstanding short interest for SEASTAR MEDICAL HOLDING CORP (ICU) is 4.31% of its float. Check the ownership tab for more information on the ICU short interest.
Over the last trailing twelve months ICU reported a non-GAAP Earnings per Share(EPS) of -12.38. The EPS decreased by -16% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -660.4% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to ICU. The Buy consensus is the average rating of analysts ratings from 5 analysts.